All posts from Zacks
Zacks in Our Research. Your Success.,

AptarGroup Looks Good on Product Strength: Time to Buy?

On Apr 4, 2016, we issued an updated research report on AptarGroup, Inc. ATR. The company will benefit from broad product diversification, expansive geographic reach and product introductions. Moreover, incessant efforts to reduce costs and lower resin prices will aid margins.

AptarGroup reported record fourth-quarter 2015 earnings per share of 67 cents which improved 18% year over year from 57 cents. Earnings also surpassed the company’s guided range of 61–66 cents. For the first quarter of 2016, AptarGroup expects earnings per share, excluding impacts from costs associated with the Mega Airless buyout, in the range of 69–74 cents.

Notably, AptarGroup will gain from product diversification, extensive geographic reach and new products in the pipeline. The company continues to expand its product portfolio within new application fields. Its airless serum dropper, originally developed for the skin market, is now featured on a new luxury hair serum product in Europe. Its nasal spray pump has been featured on the first FDA-approved, ready-to-use, needle-free nasal spray product called Narcan, a life-saving medication that can stop or reverse the effects of an opioid overdose. Also, in the home care market, AptarGroup is entering the dish care market in Asia, and sees further opportunities to grow in this space.

AptarGroup continues to see success with its closures featuring the SimpliSqueeze valve for inverted packaging. Further, the company recently helped launch several new Heinz mayonnaise and barbecue sauces in Latin America. Moreover, the company continues to expand in the bottled water market, as its closures are featured on several new plain and fruit-flavored bottled water launches globally. Overall, AptarGroup is well positioned to grow over the long term in different markets, as it leverages both its technologies and processes across its business segments.

The Pharma segment continues to benefit from the nasal spray pump being used for allergy medications going over the counter, including the newly announced Rhinocort, which had previously been a prescription-only treatment. The demand for its delivery solutions in the prescription drug and injectables markets offset weak demand from the consumer healthcare market.

AptarGroup is focused on reducing costs, while it invests in innovation and new solutions that will help its customers grow their businesses. The company also boasts a strong financial position. In 2015, the company executed its balanced capital allocation strategy. AptarGroup also completed its accelerated share repurchase program, increased its dividend and announced a strategic acquisition just after the end of 2015. Now, the company looks forward to completing the Mega Airless transaction, and moving forward with its plans to grow its Airless platform globally. Meanwhile, the company will continue to invest in projects to drive profitable growth and return value to shareholders.

At present, AptarGroup carries a Zacks Rank #2 (Buy).

Stocks that Warrant a Look

Other favorably ranked stocks in the sector are Sonoco Products Co. SON, Bemis Company, Inc. BMS and Ball Corporation BLL. All three stocks carry the same Zacks Rank as AptarGroup.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
BALL CORP (BLL): Free Stock Analysis Report
SONOCO PRODUCTS (SON): Free Stock Analysis Report
BEMIS (BMS): Free Stock Analysis Report
APTARGROUP INC (ATR): Free Stock Analysis Report
To read this article on click here.
Zacks Investment Research